Corticosteroid News and Research RSS Feed - Corticosteroid News and Research

Corticosteroids are any steroid hormones made in the adrenal cortex (the outer part of the adrenal gland). They are also made in the laboratory. Corticosteroids have many different effects in the body, and are used to treat many different conditions. They may be used as hormone replacement, to suppress the immune system, and to treat some side effects of cancer and its treatment. Corticosteroids are also used to treat certain lymphomas and lymphoid leukemias.
Long-acting inhaled combination therapy best for COPD

Long-acting inhaled combination therapy best for COPD

The combination of a long-acting β22-agonist and an inhaled corticosteroid may be the best choice for some patients with chronic obstructive pulmonary disease who need more than short-acting bronchodilators, suggest the results of a Cochrane Collaboration network meta-analysis. [More]
Study: Dietary elimination is successful method of treatment for adults with EoE

Study: Dietary elimination is successful method of treatment for adults with EoE

Dietary elimination is a successful method of treatment for adults with eosinophilic esophagitis (EoE), according to a new study1 in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. [More]
Scientists identify genes that may help predict steroid responsiveness in people with EoE

Scientists identify genes that may help predict steroid responsiveness in people with EoE

Results from a clinical trial show that high doses of the corticosteroid fluticasone propionate safely and effectively induce remission in many people with eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus characterized by high levels of white blood cells called eosinophils. [More]
Asthma inhalers may suppress children's growth

Asthma inhalers may suppress children's growth

Corticosteroid drugs that are given by inhalers to children with asthma may suppress their growth, evidence suggests. Two new systematic reviews published in The Cochrane Library focus on the effects of inhaled corticosteroid drugs (ICS) on growth rates. [More]
Pharmalink’s core patents for Nefecon issued in United States, Europe, China and Hong Kong

Pharmalink’s core patents for Nefecon issued in United States, Europe, China and Hong Kong

Pharmalink AB, a specialty pharma company focused on orphan and niche products, has had core patents for its late-stage clinical candidate Nefecon® issued in the key markets United States, Europe, China and Hong Kong. A patent is pending in Japan. [More]
Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema. [More]
FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL). [More]
Research: TB infection among people taking corticosteroid pills may be underestimated

Research: TB infection among people taking corticosteroid pills may be underestimated

Tuberculosis infection among people taking corticosteroid pills may be underestimated, new research suggests. [More]
Celsus’ expert highlights serious side effects of topical corticosteroids

Celsus’ expert highlights serious side effects of topical corticosteroids

A 2013 Mayo Clinic study involving more than 140,000 patients revealed that skin disorders are the most common nonacute reason Americans seek health care. [More]
Endocrine Society announces winners of Early Investigators Awards and FLARE Internship Awards

Endocrine Society announces winners of Early Investigators Awards and FLARE Internship Awards

The Endocrine Society is pleased to announce the recipients of the 2014 Early Investigators Awards and the Future Leaders Advancing Research in Endocrinology Internship Awards. [More]
Elevated blood eosinophil levels find to be risk factor for exacerbations in asthma patients

Elevated blood eosinophil levels find to be risk factor for exacerbations in asthma patients

In adults with persistent asthma, elevated blood eosinophil levels may be able to predict which individuals are at increased risk for exacerbations, according to a new study presented at the 2014 American Thoracic Society International Conference. [More]
FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). [More]
GSK reports positive results from Incruse Ellipta and Advair Diskus combination therapy in COPD patients

GSK reports positive results from Incruse Ellipta and Advair Diskus combination therapy in COPD patients

GlaxoSmithKline plc today presented data at the American Thoracic Society (ATS) from a late-stage clinical study. [More]
TEVA presents results from real-life, observational study of QVAR at ATS 2014 International Conference

TEVA presents results from real-life, observational study of QVAR at ATS 2014 International Conference

Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announced that results from a real-life, retrospective, observational study of QVAR- will be presented at the American Thoracic Society (ATS) 2014 International Conference in San Diego on May 18, 2014. [More]
Children who wheeze are at risk of developing damage that affect lung function

Children who wheeze are at risk of developing damage that affect lung function

Children who wheeze are at risk of developing damage that will affect their lung function by the age of 6 years, according to researchers at CHU Sainte-Justine Hospital and the University of Montreal. [More]
Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb Company today announced that new data from studies investigating its immunotherapies in adjuvant and advanced melanoma, non-small cell lung cancer (NSCLC) and metastatic renal cell carcinoma (mRCC) will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 30-June 3. [More]
Study: Asthma is associated with reduced bone mineral density

Study: Asthma is associated with reduced bone mineral density

Some of the 26 million Americans with asthma may also be prone to bone loss. According to a study published today in the May issue of Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology, there seems to be association between asthma and a decrease in bone mineral density. [More]
Teva's DuoResp Spiromax receives EC marketing authorization for treatment of asthma, COPD

Teva's DuoResp Spiromax receives EC marketing authorization for treatment of asthma, COPD

Teva Pharmaceutical Industries Ltd., announced today that the European Commission has granted marketing authorization for DuoResp Spiromax for the treatment of patients with asthma and chronic obstructive pulmonary disease (COPD) where the use of a combination of an inhaled corticosteroid and long-acting beta2-adrenoceptor agonist is appropriate. [More]
Australian and New Zealand patients with diabetes-induced vision loss to get access to new treatment

Australian and New Zealand patients with diabetes-induced vision loss to get access to new treatment

Australian and New Zealand patients suffering from vision impairment due to a type of diabetes-induced eye disease will have access to a new treatment, following a license deal between Australian biopharmaceutical company Specialised Therapeutics Australia and Alimera Sciences. [More]
Mayo Clinic research shows RA patients more likely to develop chronic kidney disease

Mayo Clinic research shows RA patients more likely to develop chronic kidney disease

Rheumatoid arthritis patients are likelier than the average person to develop chronic kidney disease, and more severe inflammation in the first year of rheumatoid arthritis, corticosteroid use, high blood pressure and obesity are among the risk factors, new Mayo Clinic research shows. [More]